On-treatment derived neutrophil-to-lymphocyte ratio and survival with palbociclib and endocrine treatment: analysis of a multicenter retrospective cohort and the PALOMA-2/3 study with immune correlates.
Chang Gon KimMin Hwan KimJee Hung KimSeul-Gi KimGun Min KimTae Yeong KimWon-Ji RyuJee Ye KimHyung Seok ParkSeho ParkYoung Up ChoByeong Woo ParkSeung Il KimJoon JeongJoohyuk SohnPublished in: Breast cancer research : BCR (2023)
On-treatment dNLR significantly predicted PFS in patients with HR-positive, HER2-negative ABC receiving palbociclib and endocrine treatment. Additionally, we observed putative systemic immune responses elicited by palbociclib, suggesting immunologic changes upon CDK4/6 inhibitor treatment.